Der Pathologe

, Volume 30, Issue 1, pp 49–55

Prognostische und prädiktive Faktoren invasiver Mammakarzinome

Update 2009
Schwerpunkt: Mammapathologie

Zusammenfassung

Prognosefaktoren geben Informationen über den Krankheitsverlauf (Rezidivfreiheit und Gesamtüberleben), die unabhängig von der Therapie sind. Zu ihnen gehören der axilläre Lymphknotenstatus, Tumordurchmesser und histologischer Differenzierungsgrad, Lymph- und Blutgefäßinvasion sowie das Staging – Faktoren, die alle durch den Pathologen bestimmt werden. Der „Nottingham Prognostic Index“ (NPI) vereint die stärksten Prognosefaktoren und ist nach Studienergebnissen als Modell für die Brustkrebsprognose geeignet.

Prädiktive Faktoren sagen die Wahrscheinlichkeit des Ansprechens eines Tumors auf eine bestimmte Therapie voraus. Hierzu gehören der Hormonrezeptorstatus, die Invasionsmarker uPA/PAI-1, der Nachweis von isolierten Tumorzellen, ein Residualtumor und der histologische Resektionsrand.

Prognostische oder prädiktive Faktoren sind klinisch relevant, wenn durch ihre Kenntnis Therapieentscheidungen ermöglicht werden, die zu einer Verbesserung des Gesamtüberlebens, des rezidivfreien Überlebens oder der Lebensqualität führen. Die internationale Konsensempfehlung von St. Gallen 2007 fordert als Grundlage für risikoadaptierte Therapieentscheidungen: Tumorgröße, Grad, Alter, Nodalstatus, Hormonrezeptorstatus sowie Her2-Überexpressions- oder -Amplifikationsstatus.

Schlüsselwörter

Gesamtüberleben Lebensqualität REMARK-Kriterien Therapieentscheidung Staging Nottingham Prognostic Index 

Prognostic and predictive factors of invasive breast cancer

Update 2009

Abstract

Prognostic factors supply information on the course of a disease (recurrence-free and total survival) and are independent of the therapy. The most important prognostic factors are lymph node status, tumor diameter and histological differentiation stage, lymph and blood vessel invasion as well as staging, factors which can all be determined by pathologists. The Nottingham prognostic index (NPI) combines the strongest prognostic factors and according to study results is a suitable model for prognosis of breast cancer.

Predictive factors give prior information on the probability of the response of a tumor to a defined therapy and include hormone receptor status, the invasion marker uPA/PAI-1, detection of isolated tumor cells, a residual tumor and the histological resection border.

Prognostic or predictive factors are clinically relevant when therapy decisions are made possible by their recognition, which lead to an improvement in the total survival, recurrence-free survival or quality of life. The international consensus recommendation of St. Gallen 2007 requires the following as a basis for risk-adapted therapy decisions: tumor size, stage, age, nodal status, hormone receptor status and Her2 overexpression or amplification status.

Keywords

Total survival Quality of life REMARK criteria Therapy decisions Staging Nottingham prognostic index 

Literatur

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74–108PubMedCrossRefGoogle Scholar
  2. 2.
    Botha JL, Bray F, Sankila R, Parkin DM (2003) Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 39:1718–1729PubMedCrossRefGoogle Scholar
  3. 3.
    American Cancer Society (2005) Cancer facts and figures 2005. American Cancer Society, Atlanta/GAGoogle Scholar
  4. 4.
    Clark GM (1994) Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 30:117–126PubMedCrossRefGoogle Scholar
  5. 5.
    Henderson IC, Patek AJ (1998) The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 52:261–288PubMedCrossRefGoogle Scholar
  6. 6.
    Gasparini G, Pozza F, Harris AL (1993) Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206–1219PubMedCrossRefGoogle Scholar
  7. 7.
    Hayes DF, Trock B, Harris AL (1998) Assessing the clinical impact of prognostic factors: when is „statistically significant“ clinically useful? Breast Cancer Res Treat 52:305–319PubMedCrossRefGoogle Scholar
  8. 8.
    Altman DG (2001) Systematic reviews in health care: Systematic reviews of evaluations of prognostic variables. Br Med J 323:224–228CrossRefGoogle Scholar
  9. 9.
    Hayes DF, Bast RC, Desch CE et al (1996) Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers 2. J Natl Cancer Inst 88:1456–1466PubMedCrossRefGoogle Scholar
  10. 10.
    McShane LM, Altman DG, Sauerbrei W (2005) Identification of clinically useful cancer prognostic factors: What are we missing? J Natl Cancer Inst 97:1023–1025PubMedCrossRefGoogle Scholar
  11. 11.
    McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180–1184PubMedGoogle Scholar
  12. 12.
    Subramaniam DS, Isaacs C (2005) Utilizing prognostic and predictive factors in breast cancer. Curr Treat Options Oncol 6:147–159PubMedCrossRefGoogle Scholar
  13. 13.
    Cawson JN, Malara F, Kavanagh A et al (2003) Fourteen-gauge needle core biopsy of mammographically evident radial scars: is excision necessary? Cancer 97:345–351PubMedCrossRefGoogle Scholar
  14. 14.
    Harris L, Fritsche H, Mennel R et al (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312PubMedCrossRefGoogle Scholar
  15. 15.
    Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144PubMedCrossRefGoogle Scholar
  16. 16.
    (o A) (2008) Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland. Zuckschwerdt, MünchenGoogle Scholar
  17. 17.
    Arriagada R, Le MG, Dunant A et al (2006) Twenty-five years of follow-up in patients with operable breast carcinoma: correlation between clinicopathologic factors and the risk of death in each 5-year period 7. Cancer 106:743–750PubMedCrossRefGoogle Scholar
  18. 18.
    Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases 3. Cancer 63:181–187PubMedCrossRefGoogle Scholar
  19. 19.
    van der Heiden-van der Loo, Bezemer PD, Hennipman A et al (2006) Introduction of sentinel node biopsy and stage migration of breast cancer. Eur J Surg Oncol 32:710–714CrossRefGoogle Scholar
  20. 20.
    Rosen PP, Groshen S, Kinne DW, Norton L (1993) Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 11:2090–2100PubMedGoogle Scholar
  21. 21.
    Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S (1995) Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol 13:1144–1151PubMedGoogle Scholar
  22. 22.
    Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRefGoogle Scholar
  23. 23.
    Frierson HF Jr, Wolber RA, Berean KW et al (1995) Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 103:195–198PubMedGoogle Scholar
  24. 24.
    Ellis IO, Coleman D, Wells C et al (2006) Impact of a national external quality assessment scheme for breast pathology in the UK. J Clin Pathol 59:138–145PubMedCrossRefGoogle Scholar
  25. 25.
    Dalton LW, Pinder SE, Elston CE et al (2000) Histologic grading of breast cancer: Linkage of patient outcome with level of pathologist agreement. Mod Pathol 13:730–735PubMedCrossRefGoogle Scholar
  26. 26.
    Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 1991; 19:403–410. Author Commentary. Histopathology 19:403–410CrossRefGoogle Scholar
  27. 27.
    Rakha EA, El-Sayed ME, Lee AHS et al (2008) Prognostic significance of nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26:3153–3158PubMedCrossRefGoogle Scholar
  28. 28.
    Haybittle JL, Blamey RW, Elston CW et al (1982) A prognostic index in primary breast cancer. Br J Cancer 45:361–366PubMedGoogle Scholar
  29. 29.
    Rosen PP, Groshen S, Kinne DW, Norton L (1993) Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 11:2090–2100PubMedGoogle Scholar
  30. 30.
    Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from national surgical adjuvant breast and bowel project protocol B-06 3. J Clin Oncol 6:1076–1087PubMedGoogle Scholar
  31. 31.
    Surveillance, Epidemiology, End Results SEER Program (2007) Relative survival rates by stage at diagnosis for breast cancer. National cancer institute, DCCPS, Surveillance research program, Cancer statistics branch. Ref Type: Electronic citation, http://www.seer.cancer.gov/Google Scholar
  32. 32.
    Woodward WA, Strom EA, Tucker SL et al (2003) Changes in the 2003 American joint committee on cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 21:3244–3248PubMedCrossRefGoogle Scholar
  33. 33.
    Blamey RW, Davies CJ, Elston CW et al (1979) Prognostic factors in breast cancer – the formation of a prognostic index. Clin Oncol 5:227–236PubMedGoogle Scholar
  34. 34.
    Lee AH, Ellis IO (2008) The Nottingham Prognostic Index for invasive carcinoma of the breast. Pathol Oncol Res14:113–115CrossRefGoogle Scholar
  35. 35.
    D’Eredita G, Giardina C, Martellotta M et al (2001) Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 37:591–596CrossRefGoogle Scholar
  36. 36.
    Lundin J (2007) The Nottingham prognostic index - from relative to absolute risk prediction. Eur J Cancer 43:1498–1500PubMedCrossRefGoogle Scholar
  37. 37.
    Holli K, Blamey RW, Mitchell MJ et al (2007) External validation in ONCOPOOL of updated survival according to the Nottingham Prognostic Index (NPI) (Abstract). Eur J Cancer (Suppl 5):19Google Scholar
  38. 38.
    Blamey RW, Ellis IO, Pinder SE et al (2007) Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990–1999. Eur J Cancer 43:1548–1555PubMedCrossRefGoogle Scholar
  39. 39.
    Eden P, Ritz C, Rose C et al (2004) Good Old clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40:1837–1841PubMedCrossRefGoogle Scholar
  40. 40.
    Ioannidis JP (2005) Microarrays and molecular research: noise discovery? 2. Lancet 365:454–455PubMedGoogle Scholar
  41. 41.
    Reis-Filho JS, Westbury C, Pierga JY (2006) The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol 59:225–231PubMedCrossRefGoogle Scholar
  42. 42.
    McGuire WL, Tandon AK, Allred DC et al (1990) How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82:1006–1015PubMedCrossRefGoogle Scholar
  43. 43.
    Hilsenbeck SG, Ravdin PM, de Moor CA et al (1998) Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52:227–237PubMedCrossRefGoogle Scholar
  44. 44.
    Hayes DF, Thor AD (2002) c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 29:231–245PubMedCrossRefGoogle Scholar
  45. 45.
    Jänicke F, Prechtl A, Thomssen C et al (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 1. J Natl Cancer Inst 93:913–920PubMedCrossRefGoogle Scholar
  46. 46.
    Wolff AC, Hammond ME, Schwartz JN et al (2007) American society of clinical Oncology/College of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145PubMedCrossRefGoogle Scholar
  47. 47.
    Borgen E, Beiske K, Trachsel S et al (1998) Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol 185:427–434PubMedCrossRefGoogle Scholar
  48. 48.
    Braun S, Pantel K, Muller P et al (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525–533PubMedCrossRefGoogle Scholar
  49. 49.
    Redmond KC, Wang JH, Austin KK et al (2001) Is immunohistochemical analysis an appropriate diagnostic technique for bone marrow micrometastases? J Clin Oncol 19:3589–3592PubMedGoogle Scholar
  50. 50.
    Braun S, Vogl FD, Naume B et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer 14. N Engl J Med 353:793–802PubMedCrossRefGoogle Scholar
  51. 51.
    Cristofanilli M, Budd GT, Ellis MJ et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer 6. N Engl J Med 351:781–791PubMedCrossRefGoogle Scholar
  52. 52.
    Budd GT, Cristofanilli M, Ellis MJ et al (2006) Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer 3. Clin Cancer Res 12:6403–6409PubMedCrossRefGoogle Scholar
  53. 53.
    Xenidis N, Perraki M, Kafousi M et al (2006) Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients 3. J Clin Oncol 24:3756–3762PubMedCrossRefGoogle Scholar
  54. 54.
    Colozza M, Azambuja E, Cardoso F et al (2005) Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? 3. Ann Oncol 16:1723–1739PubMedCrossRefGoogle Scholar
  55. 55.
    Wazer DE, Schmidt-Ullrich RK, Schmid CH et al (1997) The value of breast lumpectomy margin assessment as a predictor of residual tumor burden. Int J Radiat Oncol Biol Phys 38:291–299PubMedGoogle Scholar
  56. 56.
    Schnitt SJ, Connolly JL, Harris JR et al (1984) Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy. Cancer 53:1049–1057PubMedCrossRefGoogle Scholar
  57. 57.
    Schnitt SJ, Connolly JL, Khettry U et al (1987) Pathologic findings on re-excision of the primary site in breast cancer patients considered for treatment by primary radiation therapy. Cancer 59:675–681PubMedCrossRefGoogle Scholar
  58. 58.
    Schnitt SJ, Abner A, Gelman R et al (1994) The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy 1. Cancer 74:1746–1751PubMedCrossRefGoogle Scholar
  59. 59.
    Freedman G, Fowble B, Hanlon A et al (1999) Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy. Int J Radiat Oncol Biol Phys 44:1005–1015PubMedGoogle Scholar
  60. 60.
    Wazer DE, Jabro G, Ruthazer R et al (1999) Extent of margin positivity as a predictor for local recurrence after breast conserving irradiation. Radiat Oncol Investig 7:111–117PubMedCrossRefGoogle Scholar
  61. 61.
    Smitt MC, Nowels K, Carlson RW, Jeffrey SS (2003) Predictors of reexcision findings and recurrence after breast conservation. Int J Radiat Oncol Biol Phys 57:979–985PubMedGoogle Scholar
  62. 62.
    Phillips B, Ball C, Sackett D et al (2001) Levels of Evidence (May 2001). Oxford centre for evidence-based medicine. Ref Type: Internet Communication, http://www.cbm.netGoogle Scholar
  63. 63.
    Hayes DF, Ethier S, Lippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 100:237–238PubMedCrossRefGoogle Scholar
  64. 64.
    Cianfrocca M, Goldstein LJ (2004) Prognostic and predictive factors in early-stage breast cancer. Oncologist 9:606–616PubMedCrossRefGoogle Scholar
  65. 65.
    Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al (2007) Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 25:4952–4960PubMedCrossRefGoogle Scholar
  66. 66.
    Wishart GC, Greenberg DC, Britton PD et al (2008) Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? Br J Cancer 98:1741–1744PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2009

Authors and Affiliations

  1. 1.Brust-Screening-Pathologie, Gerhard-Domagk-Institut für PathologieUniversitätsklinikum MünsterMünsterDeutschland

Personalised recommendations